New hope for rare immune disorders: targeted pill shows promise
Disease control
Recruiting now
This study tests a drug called cobimetinib in children and adults with Langerhans cell histiocytosis (LCH) and related disorders that have not responded to standard treatment. Cobimetinib blocks a faulty growth signal in the cells causing the disease. The goal is to shrink tumors…
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated May 26, 2026 11:07 UTC